Hyoscine butylbromide oral
- Drugs List
- Therapeutic Indications
- Dosage
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Oral formulation of hyoscine butylbromide.
Drugs List
Therapeutic Indications
Uses
Gastro-intestinal spasm
Genito-urinary tract spasm
Irritable bowel syndrome
Unlicensed Uses
Bowel colic in palliative care
Excessive respiratory secretions
Dosage
Adults
20mg four times daily.
For the symptomatic relief of irritable bowel syndrome, the recommended starting dose is 10mg three times daily, this can be increased up to 20mg four times daily if necessary.
Children
Children aged 12 to 18 years
(See Dosage; Adults)
Children aged 6 to 12 years
10mg three times daily.
Excessive respiratory secretions in palliative care (unlicensed)
Children aged 12 to 18 years: 10mg to 20mg three to four times a day.
Children aged 5 to 12 years: 10mg three to four times a day.
Children aged 2 to 5 years: 5mg three to four times a day.
Children aged 1 month to 2 years: 300 to 500micrograms/kg three to four times a day. Maximum 5mg per dose.
Bowel colic in palliative care (unlicensed)
Children aged 12 to 18 years: 10mg to 20mg three to four times a day.
Children aged 5 to 12 years: 10mg three to four times a day.
Children aged 2 to 5 years: 5mg three to four times a day.
Children aged 1 month to 2 years: 300 to 500micrograms/kg three to four times a day. Maximum 5mg per dose.
Contraindications
Children under 6 years
Gastrointestinal obstruction
Gastrointestinal stenosis
Megacolon
Myasthenia gravis
Narrow angle glaucoma
Paralytic ileus
Precautions and Warnings
Elderly
Pyrexia
Breastfeeding
Cardiac failure
Cardiac impairment
Cardiac surgery
Diabetes mellitus
Galactosaemia
Glucose-galactose malabsorption syndrome
Hereditary fructose intolerance
Lactose intolerance
Pregnancy
Tachycardia
Thyrotoxicosis
Urinary obstruction
Advise visual disturbances may affect ability to drive or operate machinery
Not all available brands are licensed for all indications
Some formulations contain lactose
Some formulations contain sucrose
If visual disturbances occur, perform ophthalmic evaluation
Avoid long term use
Consult doctor if IBS symptoms worsen or if no improvement within 2wks
In case severe, unexplained abdominal pain persists or worsens, or occurs together with symptoms like fever, nausea, vomiting, changes in bowel movements, abdominal tenderness, decreased blood pressure, fainting, or blood in stool, medical advice should immediately be sought. Patients should seek immediate ophthalmological advice if they develop a painful, red eye with loss of vision whilst or after taking hyoscine butylbromide, as anticholinergic agents may elevate intraocular pressure in patients with undiagnosed, and therefore untreated narrow angle glaucoma.
Pregnancy and Lactation
Pregnancy
Use hyoscine butylbromide with caution during pregnancy.
The manufacturer does not recommend the use of hyoscine butylbromide during pregnancy. Animal studies have shown insufficient findings in the reproductive toxicity of hyoscine butylbromide. At the time of writing there is limited human data available. Risks are unknown.
Lactation
Use hyoscine butylbromide with caution during breastfeeding.
The manufacturer does not recommend breastfeeding whilst taking hyoscine butylbromide. At the time of writing there is limited published information on the excretion of hyoscine butylbromide and its metabolites in human milk.
Side Effects
Anaphylactic reaction
Anaphylactic shock
Disturbances in sweating
Dry mouth
Dyspnoea
Erythema
Hypersensitivity reactions
Pruritus
Rash
Skin reactions
Tachycardia
Urinary retention
Urticaria
Visual disturbances
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: January 2022
Reference Sources
Summary of Product Characteristics: Buscopan 10 mg tablets. Sanofi Consumer Healthcare. Revised November 2021.
Summary of Product Characteristics: Buscopan Cramps. Sanofi Consumer Healthcare. Revised November 2021.
Summary of Product Characteristics: Hyoscine Butylbromide 20 mg Film-coated Tablets. Morningside Healthcare Ltd. Revised November 2021.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 11 January 2022
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.